The DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index, and 1 are not checked yet.
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future
Open accessAbstract
Steady progress over four decades toward understanding the pathogenesis and clinical consequences of hepatic fibrosis has led to the expectation of effective antifibrotic drugs, yet none has been approved. Thus, an assessment of the field is timely, to clarify priorities and accelerate progress. Here, we highlight the successes to date but, more importantly, identify gaps and unmet needs, both experimentally and clinically. These include the need to better define cell–cell interactions and etiology‐specific elements of fibrogenesis and their link to disease‐specific drivers of portal hypertension. Success in treating viral hepatitis has revealed the remarkable capacity of the liver to degrade scar in reversing fibrosis, yet we know little of the mechanisms underlying this response. Thus, there is an exigent need to clarify the cellular and molecular mechanisms of fibrosis regression in order for therapeutics to mimic the liver’s endogenous capacity. Better refined and more predictive in vitro and animal models will hasten drug development. From a clinical perspective, current diagnostics are improving but not always biologically plausible or sufficiently accurate to supplant biopsy. More urgently, digital pathology methods that leverage machine learning and artificial intelligence must be validated in order to capture more prognostic information from liver biopsies and better quantify the response to therapies. For more refined treatment of NASH, orthogonal approaches that integrate genetic, clinical, and pathological data sets may yield treatments for specific subphenotypes of the disease. Collectively, these and other advances will strengthen and streamline clinical trials and better link histologic responses to clinical outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Upon removal of the underlying cause, liver fibrosis can resolve via activation of specific immune cell subsets.”
From Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredIn the citing paper
“Fibrosis and even cirrhosis can regress, as described following successful antiviral therapy in patients with chronic viral hepatitis, immunosuppression in autoimmune hepatitis, or lifestyle modifications and bariatric surgery in patients with metabolic dysfunction-associated steatohepatitis (MASH) (8–10).”
From Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy (2024) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histological grading and staging of chronic hepatitis.
Ishak, K., Baptista, A., Bianchi, L., Callea, F., Groote, J. D., Gudat, F., Denk, H., Desmet, V., Korb, G., Macsween, R. N., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,290
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationAn Algorithm for the Grading of Activity in Chronic Hepatitis C
Bédossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,107
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Self-citationMarcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Resolving the fibrotic niche of human liver cirrhosis at single-cell level
Ramachandran, P., Dobie, R., Wilson-Kanamori, J. R., Dora, E. F., Henderson, B. E. P., Luu, N. T., Portman, J. R., Matchett, K. P., Brice, M., Marwick, J. A., et al. (2019) · Nature · doi:10.1038/s41586-019-1631-3 · Cited by 1,784
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649
Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations
MacParland, S. A., Liu, J. C., Ma, X.-Z., Innes, B. T., Bartczak, A. M., Gage, B. K., Manuel, J., Khuu, N., Echeverri, J., Linares, I., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06318-7 · Cited by 1,552
Hepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Self-citationLiver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424
Liver fibrosis and repair: Immune regulation of wound healing in a solid organ
Pellicoro, A., Ramachandran, P., Iredale, J. P., & Fallowfield, J. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3623 · Cited by 1,310
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03362-0 · Cited by 1,294
A human liver cell atlas reveals heterogeneity and epithelial progenitors
Aizarani, N., Saviano, A., Sagar, Mailly, L., Durand, S., Herman, J. S., Pessaux, P., Baumert, T. F., & Grün, D. (2019) · Nature · doi:10.1038/s41586-019-1373-2 · Cited by 1,147
Cross-tissue organization of the fibroblast lineage
Buechler, M. B., Pradhan, R., Krishnamurty, A. T., Cox, C. B., Calviello, A. K., Wang, A. W., Yang, Y. A., Tam, L., Caothien, R. H., Roose‐Girma, M., et al. (2021) · Nature · doi:10.1038/s41586-021-03549-5 · Cited by 1,100
Iredale, J. P., Benyon, R. C., Pickering, J., McCullen, M., Northrop, M., Pawley, S., Hovell, C., & Arthur, M. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1018 · Cited by 1,075
Ramachandran, P., Pellicoro, A., Vernon, M. A., Boulter, L., Aucott, R. L., Ali, A., Hartland, S. N., Snowdon, V. K., Cappon, A., Gordon-Walker, T. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119964109 · Cited by 1,001
Hepatic inflammation and fibrosis: Functional links and key pathways
Seki, E., & Schwabe, R. F. (2015) · Hepatology · doi:10.1002/hep.27332 · Cited by 972
Machine Learning in Drug Discovery: A Review
Dara, S., Dhamercherla, S., Jadav, S. S., Babu, C. M., & Ahsan, M. J. (2021) · Artificial Intelligence Review · doi:10.1007/s10462-021-10058-4 · Cited by 893
Hepatic lipocytes: the principal collagen-producing cells of normal rat liver.
Friedman, S. L., Roll, F. J., Boyles, J., & Bissell, D. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.24.8681 · Cited by 859
Self-citationLipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
Xiong, X., Kuang, H., Ansari, S., Liu, T., Gong, J., Wang, S., Zhao, X.-Y., Ji, Y., Li, C., Guo, L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.028 · Cited by 784
Decoding myofibroblast origins in human kidney fibrosis
Kuppe, C., Ibrahim, M. M., Kranz, J., Zhang, X., Ziegler, S., Perales-Patón, J., Jansen, J., Reimer, K. C., Smith, J. R., Dobie, R., et al. (2021) · Nature · doi:10.1038/s41586-020-2941-1 · Cited by 769
Tsukui, T., Sun, K.-H., Wetter, J. B., Wilson-Kanamori, J. R., Hazelwood, L. A., Henderson, N. C., Adams, T. S., Schupp, J. C., Poli, S. D., Rosas, I. O., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15647-5 · Cited by 765
Younossi, Z. M., Stepanova, M., Rafiq, N., Makhlouf, H. R., Younoszai, Z., Agrawal, R., & Goodman, Z. D. (2011) · Hepatology · doi:10.1002/hep.24268 · Cited by 636
Lassailly, G., Caiazzo, R., Ntandja-Wandji, L.-C., Gnemmi, V., Baud, G., Verkindt, H., Ningarhari, M., Louvet, A., Leteurtre, E., Raverdy, V., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.006 · Cited by 622 · cited 2×
“Natural history studies in hepatitis B and C, as well as NASH, suggest that some fibrosis reduction is possible in a year or less but is greater at 5 years.[108,149,150] Moreover, whereas reversal of cirrhosis has been documented in HBV and HCV, this has not been consistently observed in NASH cirrhosis.”
BackgroundSato, Y., Murase, K., Kato, J., Kobune, M., Sato, T., Kawano, Y., Takimoto, R., Takada, K., Miyanishi, K., Matsunaga, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1396 · Cited by 621
Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease
Dudley, J. T., Sirota, M., Shenoy, M. M., Pai, R. K., Roedder, S., Chiang, A. P.-F., Morgan, A. A., Sarwal, M., Pasricha, P. J., & Butte, A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002648 · Cited by 604
Pirola, C. J., Fernández Gianotti, T., Castaño, G. O., Mallardi, P., San Martino, J., Mora Gonzalez Lopez Ledesma, M., Flichman, D., Mirshahi, F., Sanyal, A. J., & Sookoian, S. (2015) · Gut · doi:10.1136/gutjnl-2014-306996 · Cited by 564
Mózes, F. E., Lee, J. A., Selvaraj, E. A., Jayaswal, A. N. A., Trauner, M., Boursier, J., Fournier, C., Staufer, K., Stauber, R. E., Bugianesi, E., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-324243 · Cited by 556
Identification of type 2 diabetes subgroups through topological analysis of patient similarity
Li, L., Cheng, W., Glicksberg, B. S., Gottesman, O., Tamler, R., Chen, R., Böttinger, E. P., & Dudley, J. T. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa9364 · Cited by 554
Ju, C., & Tacke, F. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.104 · Cited by 554
Now there are many (stages) where before there was one
García–Tsao, G., Friedman, S. L., Iredale, J. P., & Pinzani, M. (2009) · Hepatology · doi:10.1002/hep.23478 · Cited by 539
Self-citationModeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids
Ouchi, R., Togo, S., Kimura, M., Shinozawa, T., Koido, M., Koike, H., Thompson, W., Karns, R. A., Mayhew, C. N., McGrath, P. S., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.05.007 · Cited by 537
Apoptosis: The nexus of liver injury and fibrosis
Canbay, A. E., Friedman, S. L., & Gores, G. J. (2004) · Hepatology · doi:10.1002/hep.20051 · Cited by 536
Self-citationThe role of the microbiome in NAFLD and NASH
Kolodziejczyk, A. A., Zheng, D., Shibolet, O., & Elinav, E. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809302 · Cited by 523
Microscopic examination of spatial transcriptome using Seq-Scope
Cho, C.-S., Xi, J., Si, Y., Park, S.-R., Hsu, J.-E., Kim, M., Jun, G., Kang, H. M., & Lee, J. H. (2021) · Cell · doi:10.1016/j.cell.2021.05.010 · Cited by 520
Liver sinusoidal endothelial cells in hepatic fibrosis
DeLeve, L. D. (2015) · Hepatology · doi:10.1002/hep.27376 · Cited by 482
Govaere, O., Cockell, S., Tiniakos, D., Queen, R., Younes, R., Vacca, M., Alexander, L., Ravaioli, F., Palmer, J., Petta, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4448 · Cited by 479
Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis
Dobie, R., Wilson-Kanamori, J. R., Henderson, B. E. P., Smith, J. R., Matchett, K. P., Portman, J. R., Wallenborg, K., Picelli, S., Zagorska, A., Pendem, S. V., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.024 · Cited by 420
Apoptotic Body Engulfment by a Human Stellate Cell Line Is Profibrogenic
Canbay, A., Taimr, P., Torok, N., Higuchi, H., Friedman, S., & Gores, G. J. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000069036.63405.5c · Cited by 417 · cited 1×
“These include (1) disruption of the normal ECM of the space of Disse as a consequence of hepatocyte damage and inflammatory infiltration[12,13]; (2) release of reactive oxygen species and other fibrogenic/proinflammatory mediators[14,15]; and (3) recruitment of immune cells, which in turn sustain HSC activation.”
BackgroundSelf-citationXie, G., Wang, X., Wang, L., Wang, L., Atkinson, R. D., Kanel, G. C., Gaarde, W. A., & DeLeve, L. D. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.017 · Cited by 410
DeLeve, L. D., Wang, X., & Guo, Y. (2008) · Hepatology · doi:10.1002/hep.22351 · Cited by 408
Younossi, Z. M., Loomba, R. S., Rinella, M. E., Bugianesi, E., Marchesini, G., Neuschwander‐Tetri, B. A., Serfaty, L., Negro, F., Caldwell, S. H., Ratziu, V., et al. (2017) · Hepatology · doi:10.1002/hep.29724 · Cited by 384
Self-citationReversal of Hepatic Fibrosis — Fact or Fantasy?
Friedman, S. L., & Bansal, M. B. (2006) · Hepatology · doi:10.1002/hep.20974 · Cited by 380
Self-citationAdvances in non-invasive assessment of hepatic fibrosis
Loomba, R. S., & Adams, L. A. (2020) · Gut · doi:10.1136/gutjnl-2018-317593 · Cited by 351
A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis
Oh, T. G., Kim, S. M., Caussy, C., Fu, T., Guo, J. P., Bassirian, S., Singh, S., Madamba, E. V., Bettencourt, R., Richards, L., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.005 · Cited by 344
A Gut Microbiome Signature for Cirrhosis Due to Nonalcoholic Fatty Liver Disease
Caussy, C., Tripathi, A., Humphrey, G., Bassirian, S., Singh, S., Faulkner, C., Bettencourt, R., Rizo, E., Richards, L., Xu, Z. Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09455-9 · Cited by 338
Liver fibrosis: from the bench to clinical targets
Pinzani, M., & Rombouts, K. (2004) · Digestive and Liver Disease · doi:10.1016/j.dld.2004.01.003 · Cited by 337
Self-citationMusso, G., Cassader, M., Paschetta, E., & Gambino, R. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.031 · Cited by 332
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2002-1 · Cited by 328
Cell and tissue engineering for liver disease
Bhatia, S. N., Underhill, G. H., Zaret, K. S., & Fox, I. J. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3005975 · Cited by 309
Wong, L., Yamasaki, G., Johnson, R. J., & Friedman, S. L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117497 · Cited by 304
Self-citationCasini, A., Ceni, E., Salzano, R., Biondi, P., Parola, M., Galli, A., Foschi, M., Caligiuri, A., Pinzani, M., & Surrenti, C. (1997) · Hepatology · doi:10.1002/hep.510250218 · Cited by 302
Self-citationBasuRay, S., Smagris, E., Cohen, J. C., & Hobbs, H. H. (2017) · Hepatology · doi:10.1002/hep.29273 · Cited by 302
Vali, Y., Lee, J., Boursier, J., Spijker, R., Löffler, J., Verheij, J., Brosnan, M. J., Böcskei, Z., Anstee, Q. M., Bossuyt, P. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.036 · Cited by 302
Pharmacotherapy for NASH: Current and emerging
Konerman, M. A., Jones, J. C., & Harrison, S. A. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.015 · Cited by 297
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
Rudalska, R., Dauch, D., Longerich, T., McJunkin, K., Wuestefeld, T., Kang, T.-W., Hohmeyer, A., Pesic, M., Leibold, J., von Thun, A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3679 · Cited by 282
Anstee, Q. M., Lawitz, E. J., Alkhouri, N., Wong, V. W., Romero‐Gomez, M., Okanoue, T., Trauner, M., Kersey, K., Li, G., Han, L., et al. (2019) · Hepatology · doi:10.1002/hep.30842 · Cited by 277
Saviano, A., Henderson, N. C., & Baumert, T. F. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.06.004 · Cited by 276
Harrison, S. A., Ratziu, V., Boursier, J., Francque, S., Bédossa, P., Majd, Z., Cordonnier, G., Sudrik, F. B., Darteil, R., Liebe, R., et al. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30252-1 · Cited by 270
The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells
Bruschi, F. V., Claudel, T., Tardelli, M., Caligiuri, A., Stulnig, T. M., Marra, F., & Trauner, M. (2017) · Hepatology · doi:10.1002/hep.29041 · Cited by 268
Vascular Endothelial Growth Factor Promotes Fibrosis Resolution and Repair in Mice
Yang, L., Kwon, J., Popov, Y. V., Gajdos, G. B., Ördög, T., Brekken, R. A., Mukhopadhyay, D., Schuppan, D., Bi, Y., Simonetto, D. A., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.061 · Cited by 265
Metabolomic identification of subtypes of nonalcoholic steatohepatitis
Alonso, C., Fernández-Ramos, D., Varela-Rey, M., Martínez-Arranz, I., Navasa, N., Van Liempd, S. M., Lavín Trueba, J. L., Mayo, R., Ilisso, C. P., de Juan, V. G., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.015 · Cited by 263
Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis
Ramachandran, P., Matchett, K. P., Dobie, R., Wilson-Kanamori, J. R., & Henderson, N. C. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0304-x · Cited by 253
Organs-on-a-chip models for biological research
Vunjak-Novakovic, G., Ronaldson-Bouchard, K., & Radisic, M. (2021) · Cell · doi:10.1016/j.cell.2021.08.005 · Cited by 248
AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma
Chow, R. D.-W., Guzman, C. D., Wang, G., Schmidt, F., Youngblood, M. W., Ye, L., Errami, Y., Dong, M. B., Martinez, M. A. Q., Zhang, S., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4620 · Cited by 240
The Natural History of Nonalcoholic Fatty Liver Disease - An Evolving View
Lindenmeyer, C. C., & Mccullough, A. (2018) · Clinical Liver Disease · doi:10.1016/j.cld.2017.08.003 · Cited by 240
Klein, T., Eckhard, U., Dufour, A., Solis, N., & Overall, C. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00120 · Cited by 237
Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T., Tsujinoue, H., Yanase, K., Namisaki, T., Imazu, H., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.35625 · Cited by 229
Michels, B. E., Mosa, M. H., Streibl, B. I., Zhan, T., Menche, C., Abou-El-Ardat, K., Darvishi, T., Członka, E., Wagner, S., Winter, J., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.04.003 · Cited by 222
Su, T., Yang, Y., Lai, S., Jeong, J., Jung, Y., McConnell, M., Utsumi, T., & Iwakiri, Y. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.12.007 · Cited by 220
Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease
Lang, S., Demir, M., Martin, A., Jiang, L., Zhang, X., Duan, Y., Gao, B., Wisplinghoff, H., Kasper, P., Roderburg, C., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.07.005 · Cited by 214
Imaging biomarkers of NAFLD, NASH, and fibrosis
Ajmera, V. H., & Loomba, R. S. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101167 · Cited by 214
Scraping fibrosis: Expressway to the core of fibrosis
Mehal, W. Z., Iredale, J. P., & Friedman, S. L. (2011) · Nature Medicine · doi:10.1038/nm0511-552 · Cited by 206
Self-citationIredale, J. P., Murphy, G., Hembry, R. M., Friedman, S. L., & Arthur, M. J. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115850 · Cited by 202
Self-citationApplication of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases
Ahn, J. C., Connell, A., Simonetto, D. A., Hughes, C., & Shah, V. H. (2020) · Hepatology · doi:10.1002/hep.31603 · Cited by 201
Interactions Between Hepatic Stellate Cells and the Immune System
Maher, J. J. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-17555 · Cited by 198
Taylor-Weiner, A. N., Pokkalla, H., Han, L., Jia, C., Huss, R. S., Chung, C., Elliott, H. L., Glass, B., Pethia, K., Carrasco‐Zevallos, O. M., et al. (2021) · Hepatology · doi:10.1002/hep.31750 · Cited by 194
Matrix Metalloproteinases as Potential Biomarkers and Therapeutic Targets in Liver Diseases
Geervliet, E., & Bansal, R. (2020) · Cells · doi:10.3390/cells9051212 · Cited by 182
Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis
Siller-López, F., Sandoval-Rodriguez, A. S., Salgado, S., Salazar, A., Bueno‐Topete, M. R., Garcı́a, J., Vera-Cruz, J. M., Gálvez, J., Hernández‐Cañaveral, I., & Ramos, M. H. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.12.045 · Cited by 173
Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Abdelmalek, M. F., Ding, D., Han, L., Jia, C., Huss, R. S., Chung, C., et al. (2022) · Hepatology · doi:10.1002/hep.32204 · Cited by 171
Mayo, R., Crespo, J., Martínez‐Arranz, I., Bañales, J. M., Arias, M., Mincholé, I., de la Fuente, R. A., Jiménez-Agüero, R., Alonso, C., de Luis, D. A., et al. (2018) · Hepatology Communications · doi:10.1002/hep4.1188 · Cited by 170
Matrix metalloproteinase functions in hepatic injury and fibrosis
Roderfeld, M. (2017) · Matrix Biology · doi:10.1016/j.matbio.2017.11.011 · Cited by 168
Large-scale proteomics identifies MMP-7 as a sentinel of epithelial injury and of biliary atresia
Lertudomphonwanit, C., Mourya, R., Fei, L., Zhang, Y., Gutta, S., Yang, L., Bove, K. E., Shivakumar, P., & Bezerra, J. A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8462 · Cited by 167
Pathophysiology of Liver Fibrosis
Pinzani, M. (2015) · Digestive Diseases · doi:10.1159/000374096 · Cited by 164
Self-citationFibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside
Rockey, D. C., & Friedman, S. L. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.09.065 · Cited by 157
Self-citationAT1R–CB1R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II
Rozenfeld, R., Gupta, A., Gagnidze, K., Lim, M. P., Gomes, I., Ramos‐Ortolaza, D. L., Nieto, N., & Devi, L. A. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.139 · Cited by 155
Dendritic Cell Regulation of Carbon Tetrachloride–Induced Murine Liver Fibrosis Regression
Jiao, J., Sastre, D., Fiel, M. I., Lee, U. E., Ghiassi–Nejad, Z., Ginhoux, F., Vivier, E., Friedman, S. L., Merad, M., & Aloman, C. (2012) · Hepatology · doi:10.1002/hep.24621 · Cited by 154
Self-citationHan, Y.-H., Shin, K.-O., Kim, J.-Y., Khadka, D. B., Kim, H.-J., Lee, Y.-M., Cho, W.-J., Cha, J.-Y., Lee, B.-J., & Lee, M.-O. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124219 · Cited by 154
Beljaars, L., Molema, G., Schuppan, D., Geerts, A. E., Bleser, P. J. D., Weert, B., Meijer, D. K. F., & Poelstra, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.17.12743 · Cited by 146
Heterogeneity of HSCs in a Mouse Model of NASH
Rosenthal, S. B., Liu, X., Ganguly, S., Dhar, D., Pasillas, M. P., Ricciardelli, E., Li, R. Z., Troutman, T. D., Kisseleva, T., Glass, C. K., et al. (2021) · Hepatology · doi:10.1002/hep.31743 · Cited by 145
Tsochatzis, E. A., Bruno, S., Isgrò, G., Hall, A. R., Theocharidou, E., Manousou, P., Dhillon, A. P., Burroughs, A. K., & Luong, T. V. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.023 · Cited by 140
Epigenetics and Liver Fibrosis
Morán‐Salvador, E., & Mann, J. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.04.007 · Cited by 140
Eng, J., & Estall, J. L. (2021) · Cells · doi:10.3390/cells10071805 · Cited by 136
Lee, Y. A., & Friedman, S. L. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.03.012 · Cited by 132
Self-citationLoft, A., Alfaro, A. J., Schmidt, S. F., Pedersen, F. B., Terkelsen, M. K., Puglia, M., Chow, K. K., Feuchtinger, A., Troullinaki, M., Maida, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.06.005 · Cited by 129
Update on the pathophysiology of liver fibrosis
Pinzani, M., & Macías‐Barragán, J. (2010) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.10.47 · Cited by 126
Self-citationFerrusquía‐Acosta, J., Bassegoda, O., Turco, L., Reverter, E., Pellone, M., Bianchini, M., Pérez‐Campuzano, V., Ripoll, E., García‐Criado, Á., Graupera, I., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.10.003 · Cited by 123
Decharatanachart, P., Chaiteerakij, R., Tiyarattanachai, T., & Treeprasertsuk, S. (2021) · BMC Gastroenterology · doi:10.1186/s12876-020-01585-5 · Cited by 114
Inverso, D., Shi, J., Lee, K. H., Jakab, M., Ben-Moshe, S., Kulkarni, S. R., Schneider, M., Wang, G., Komeili, M., Vélez, P. A., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.05.001 · Cited by 114
Modeling Disease In Vivo With CRISPR/Cas9
Dow, L. E. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.07.006 · Cited by 111
Mazza, G., Al‐Akkad, W., Telese, A., Longato, L., Urbani, L., Robinson, B. K., Hall, A. R., Kong, K., Frenguelli, L., Marrone, G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05134-1 · Cited by 110
Self-citationArtificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers
Caldéraro, J., & Kather, J. N. (2020) · Gut · doi:10.1136/gutjnl-2020-322880 · Cited by 108
A Bioreactor Technology for Modeling Fibrosis in Human and Rodent Precision‐Cut Liver Slices
Paish, H. L., Reed, L. H., Brown, H., Bryan, M. C., Govaere, O., Leslie, J., Barksby, B. S., Garcia Macia, M., Watson, A., Xu, X., et al. (2019) · Hepatology · doi:10.1002/hep.30651 · Cited by 106
Gradually softening hydrogels for modeling hepatic stellate cell behavior during fibrosis regression
Caliari, S. R., Perepelyuk, M., Soulas, E. M., Lee, G. Y., Wells, R. G., & Burdick, J. A. (2016) · Integrative Biology · doi:10.1039/c6ib00027d · Cited by 100
van de Bovenkamp, M., Groothuis, G. M. M., Draaisma, A. L., Merema, M. T., Bezuijen, J. I., van Gils, M. J., Meijer, D. K. F., Friedman, S. L., & Olinga, P. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi127 · Cited by 95
Self-citationShameer, K., Readhead, B., & Dudley, J. T. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150112103510 · Cited by 93
Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?
Ratziu, V., & Friedman, S. L. (2023) · Gastroenterology · doi:10.1053/j.gastro.2020.05.046 · Cited by 88
Self-citationEndophenotype Network Models: Common Core of Complex Diseases
Ghiassian, S. D., Menche, J., Chasman, D. I., Giulianini, F., Wang, R., Ricchiuto, P., Aikawa, M., Iwata, H., Müller, C., Zeller, T., et al. (2016) · Scientific Reports · doi:10.1038/srep27414 · Cited by 86
Novo, E., Povero, D., Busletta, C., Paternostro, C., di Bonzo, L. V., Cannito, S., Compagnone, A., Bandino, A., Marra, F., Colombatto, S., et al. (2011) · The Journal of Pathology · doi:10.1002/path.3005 · Cited by 85
Self-citationLiver fibrosis and Gd-EOB-DTPA-enhanced MRI: A histopathologic correlation
Verloh, N., Utpatel, K., Haimerl, M., Zeman, F., Fellner, C., Fichtner‐Feigl, S., Teufel, A., Stroszczynski, C., Evert, M., & Wiggermann, P. (2015) · Scientific Reports · doi:10.1038/srep15408 · Cited by 80
Cheung, A. C., Neuschwander‐Tetri, B. A., Kleiner, D. E., Schabel, E., Rinella, M. E., Harrison, S. A., Ratziu, V., Sanyal, A. J., Loomba, R. S., Megnien, S. J., et al. (2019) · Hepatology · doi:10.1002/hep.30672 · Cited by 77
Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging
Li, D., He, L., Guo, H., Chen, H., & Shan, H. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0151-x · Cited by 74
Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases
Wooden, B., Goossens, N., Hoshida, Y., & Friedman, S. L. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.065 · Cited by 69
Self-citationMazza, G., Telese, A., Al‐Akkad, W., Frenguelli, L., Levi, A., Marrali, M., Longato, L., Thanapirom, K., Vilia, M. G., Lombardi, B., et al. (2019) · Cells · doi:10.3390/cells9010083 · Cited by 69
Self-citationModeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review
Carreres, L., Jílková, Z. M., Vial, G., Marche, P. N., Decaens, T., & Lerat, H. (2021) · Biomedicines · doi:10.3390/biomedicines9040378 · Cited by 68
MMP Inhibitors Past present and future
Cao, J. P. (2015) · Frontiers in bioscience · doi:10.2741/4365 · Cited by 66
Bosch, J., Chung, C., Carrasco‐Zevallos, O. M., Harrison, S. A., Abdelmalek, M. F., Shiffman, M. L., Rockey, D. C., Shanis, Z., Juyal, D., Pokkalla, H., et al. (2021) · Hepatology · doi:10.1002/hep.32087 · Cited by 65
Villesen, I. F., Daniels, S. J., Leeming, D. J., Karsdal, M. A., & Nielsen, M. J. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15773 · Cited by 63
Chen, I. M., Willumsen, N., Dehlendorff, C., Johansen, A. Z., Jensen, B. V., Hansen, C. P., Hasselby, J. P., Bojesen, S. E., Pfeiffer, P., Nielsen, S. E., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32751 · Cited by 62
Ferrandino, G., Orf, I., Smith, R., Calcagno, M., Thind, A. K., Debiram–Beecham, I., Williams, M., Gandelman, O. A., de Saedeleer, A., Kibble, G., et al. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000239 · Cited by 59
Role of Angiogenesis in the Pathogenesis of NAFLD
Lei, L., Mourabit, H. E., Housset, C., Cadoret, A., & Lemoinne, S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071338 · Cited by 53
Fibrosis distribution in explanted cirrhotic livers
Hall, A. R., Germani, G., Isgrò, G., Burroughs, A. K., & Dhillon, A. P. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.04094.x · Cited by 47
Cell‐type‐resolved proteomic analysis of the human liver
Ölander, M., Wiśniewski, J. R., & Artursson, P. (2020) · Liver International · doi:10.1111/liv.14452 · Cited by 47
Directed differentiation of human induced pluripotent stem cells to hepatic stellate cells
Vallverdú, J., de la Torre, R. A. M. G., Mannaerts, I., Verhulst, S., Smout, A., Coll, M., Ariño, S., Rubio‐Tomás, T., Aguilar‐Bravo, B., Martínez–Sánchez, C., et al. (2021) · Nature Protocols · doi:10.1038/s41596-021-00509-1 · Cited by 47
Portal myofibroblasts connect angiogenesis and fibrosis in liver
Lemoinne, S., Thabut, D., & Housset, C. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2443-5 · Cited by 46
Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution
Musso, G., Gambino, R., Cassader, M., Paschetta, E., & Sircana, A. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.01.003 · Cited by 46
The gut mycobiome: a novel player in chronic liver diseases
Jiang, L., Stärkel, P., Fan, J., Fouts, D. E., Bächer, P., & Schnabl, B. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01740-5 · Cited by 42
The Versatile Role of Matrix Metalloproteinase for the Diverse Results of Fibrosis Treatment
Chuang, H.-M., Chen, Y.-S., & Harn, H. (2019) · Molecules · doi:10.3390/molecules24224188 · Cited by 41
Hicks, D. F., Goossens, N., Blas‐García, A., Tsuchida, T., Wooden, B., Wallace, M. C., Nieto, N., Lade, A. G., Redhead, B., Cederbaum, A. I., et al. (2017) · Scientific Reports · doi:10.1038/srep42563 · Cited by 40
Self-citationCurrent and new pharmacotherapy options for non-alcoholic steatohepatitis
Sumida, Y., Yoneda, M., Ogawa, Y., Yoneda, M., Okanoue, T., & Nakajima, A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1744564 · Cited by 39
Hou, X., Yang, Y., Li, P., Zeng, Z., Hu, W., Zhe, R., Liu, X., Tang, D., Ou, M., & Dai, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.652408 · Cited by 39
Aguado, D. M., Rodríguez, A., Mestre‐Alagarda, C., Bauza, M. E., Valero‐Pérez, E., Alfaro‐Cervelló, C., Benlloch, S., Pérez‐Rojas, J., Ferrández, A., Monraval, P. A., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16100 · Cited by 39
Bone marrow-derived fibrocytes contribute to liver fibrosis
Xu, J., & Kisseleva, T. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215584933 · Cited by 37
Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives
He, N.-Y., Li, Q., Wu, C., Ren, Z., Gao, Y., Pan, L.-H., Wang, M., Wen, H.-Y., Jiang, Z., Tang, Z., et al. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.134 · Cited by 33
STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus
Rinella, M. E., & Noureddin, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.034 · Cited by 33
Besutti, G., Valenti, L. V. C., Ligabue, G., Bassi, M. C., Pattacini, P., Guaraldi, G., & Rossi, P. G. (2019) · Liver International · doi:10.1111/liv.14118 · Cited by 30
Predicting clinical decompensation in patients with cirrhosis using the Hepquant‐SHUNT test
Fallahzadeh, M. A., Hansen, D. J., Trotter, J. F., Everson, G. T., Saracino, G., Rahimi, R. S., Helmke, S. M., Boutté, J., & Asrani, S. K. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16283 · Cited by 28
Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
Albhaisi, S., & Sanyal, A. J. (2019) · Pharmaceutical Medicine · doi:10.1007/s40290-019-00305-z · Cited by 27
Wieland, A., Etzion, O., Ali, R. O., Levy, E., Kleiner, D. E., Helmke, S. M., Heller, T., & Everson, G. T. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.04.030 · Cited by 23
Cazanave, S. C., Warren, A. D., Pacula, M., Touti, F., Zagorska, A., Gural, N., Huang, E. K., Sherman, S., Cheema, M., Ibarra, S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe8939 · Cited by 23
Bhattacharya, D., Becker, C., Readhead, B. P., Goossens, N., Buros, J. L., Fiel, M. I., Cousens, L. P., Magnusson, B., Backmark, A., Hicks, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99008-2 · Cited by 20
Self-citationManagement of Idiopathic Pulmonary Fibrosis
Salisbury, M. L., & Wijsenbeek, M. S. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.004 · Cited by 20
Stravitz, R. T., & Ilan, Y. (2016) · Liver International · doi:10.1111/liv.13268 · Cited by 18
PET/SPECT Molecular Probes for the Diagnosis and Staging of Nonalcoholic Fatty Liver Disease
Shao, T., Josephson, L., & Liang, S. H. (2019) · Molecular Imaging · doi:10.1177/1536012119871455 · Cited by 18
Collagen-targeted molecular imaging in diffuse liver diseases
Zhou, I. Y., Tanabe, K. K., Fuchs, B. C., & Caravan, P. (2020) · Abdominal Radiology · doi:10.1007/s00261-020-02677-2 · Cited by 14
Li, X., Liu, H., Wang, R., Yang, J., Zhang, Y., & Li, C. (2019) · Clinical Radiology · doi:10.1016/j.crad.2019.11.001 · Cited by 11
Turner, R. J., Gölz, S., Wollnik, C., Burkhardt, N., Sternberger, I., Andag, U., & Cornils, H. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220915851 · Cited by 9
Ten Thousand Points of Light: Heterogeneity Among the Stars of NASH Fibrosis
Carter, J., Wang, S., & Friedman, S. L. (2021) · Hepatology · doi:10.1002/hep.31807 · Cited by 8
Self-citation
Research works printed but not linked: 3
- 1970, Hepatic fibrosis. Correlation of biochemical and morphologic investigations, Am J Med, 49, 707
- 2021, The Tabula Sapiens: a single cell transcriptomic atlas of multiple organs from individual human donors, bioRxiv
- 2020, Why do so many NASH trials fail?, Gastroenterology
Cited by
Sorted by citations
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 239
Self-citationWang, Y., Hu, J., Wu, S., Fleishman, J. S., Li, Y., Xu, Y.-S., Zou, W., Wang, J., Feng, Y., Chen, J., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01720-0 · Cited by 225
Akkız, H., Gieseler, R. K., & Canbay, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147873 · Cited by 191
The Evolution of Single-Cell RNA Sequencing Technology and Application: Progress and Perspectives
Wang, S., Sun, S.-T., Zhang, X., Ding, H.-R., Yu, Y., He, J., Wang, M.-S., Yang, B., & Li, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032943 · Cited by 183
Mechanisms of organ fibrosis: Emerging concepts and implications for novel treatment strategies
Lurje, I., Gaisa, N. T., Weiskirchen, R., & Tacke, F. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101191 · Cited by 152
Metadata
- Authors
- Friedman, S. L., & Pinzani, M.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- University College London (GB)
- Corresponding author
- Friedman, Scott L.
- Pinzani, Massimo
- Venue
- Hepatology
- Published
- 2022-01-11
- Volume
- 75
- Issue
- 2
- Pages
- 473-488
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- PMC
- PMC12179971
- OpenAlex
- W4200351549
- Cited by
- 430
- References
- 147
- Citations by year
- 2026: 83 · 2025: 76 · 2024: 104 · 2023: 129 · 2022: 37
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK128289)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- liver fibrosis, antifibrotic agents, fibrogenesis, portal hypertension, fibrosis regression, viral hepatitis, liver regeneration, fibrosis diagnosis, liver biopsy, digital pathology, machine learning, artificial intelligence, nonalcoholic steatohepatitis, clinical trials
- MeSH terms
- Drug Development, Antifibrotic Agents, Animals, Clinical Trials as Topic, Fibrosis, Humans, Liver, Liver Cirrhosis, Needs Assessment, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
